Search

State

Industry

Company

LABORATORY ANALYTICAL INSTRUMENTS

CONFIDENTIAL [*] = CERTAIN INFORMATION

Illumina Inc

CONFIDENTIAL [*] = CERTAIN INFORMATION IN THIS HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. COLLABORATION AGREEMENT This COLLABORATION AGREEMENT (this "Agreement") is made effective as of the 17th day of December, 2004 (the "Effective Date") by and among ILLUMINA, INC., a Delaware corporation having its

PHARMACEUTICAL PREPARATIONS

CLINICAL TRIAL COLLABORATION AGREEMENT

Nektar Therapeutics

nktr-ex101_8.htm ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 CLINICAL TRIAL COLLABORATION AGREEMENT This Clinical Trial Collaboration Agreement (the “ Agreement ”) is made and entered into effective as of September 21, 2016 (the “ Effective Date ”) by and between Nektar Thera

PHARMACEUTICAL PREPARATIONS

STRATEGIC COLLABORATION AGREEMENT

Nektar Therapeutics

nktr-ex101_104.htm STRATEGIC COLLABORATION AGREEMENT BY AND BETWEEN Nektar Therapeutics AND Bristol-Myers Squibb Company DATED FEBRUARY 13, 2018 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. TABLE OF CONTENTS Article 1 DEFINITIONS 1 Articl

BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Confidential Materials omitted and filed

Biogen Inc.

exv10w5 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. SECOND AMENDED AND RESTATED COLLABORATION AGREEMENT GENENTECH, INC. AND BIOGEN IDEC INC. -1- COLLABORATION AGREEMENT THIS SECOND AMENDED AND RESTATED COLLABORATION AGREEMENT (this “Agreement) is made effective as of the 18th day of October, 2010 (the “Second Restate

PHARMACEUTICAL PREPARATIONS

Amendment No. 5 to the Restated Dev. and Com. Collaboration Agmt.

Bristol Myers Squibb Co

AMENDMENT NO. 5 TO THE RESTATED DEV. AND COM. COLLABORATION AGMT. Amendment No. 5 to the Restated Dev. and Com. Collaboration Agmt. * CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION AMENDMENT NO. 5 TO THE RESTATED DEVELOPMENT AND COMMERCIALIZATION COLLABORATION AGREEMENT THIS AMENDMENT NO. 5 (“ Amendment ”) to that certai

PHARMACEUTICAL PREPARATIONS

Amendment No. 3 to the Restated Dev. and Com. Collaboration Agmt.

Bristol Myers Squibb Co

AMENDMENT NO. 3 TO THE RESTATED DEV. AND COM. COLLABORATION AGMT. Amendment No. 3 to the Restated Dev. and Com. Collaboration Agmt. * CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION AMENDMENT NO. 3 TO THE RESTATED DEVELOPMENT AND COMMERCIALIZATION COLLABORATION AGREEMENT THIS AMENDMENT NO. 3 (“Amendment”) to that certain

PHARMACEUTICAL PREPARATIONS

BINDING MEMORANDUM OF UNDERSTANDING

Alexion Pharmaceuticals, Inc.

BINDING MEMORANDUM OF UNDERSTANDING CONFIDENTIAL TREATMENT MEMORANDUM OF UNDERSTANDING Revised P&GP / Alexion Pexelizumab Collaboration This Memorandum represents a summary of the Parties' interests in renegotiating their current Collaboration and it is binding as set forth in the final paragraph hereof. OVERVIEW AND MANAGEMENT OF THE COLLABORATION Scope: P&GP and Alexion propose to revise the Col

BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

AMENDMENT 1 TO COLLABORATION AGREEMENT

Amgen Inc

AMENDMENT 1 TO COLLABORATION AGREEMENT AMGN-EX10.58_2012.12.31 10K Amendment No. 1 to Collaboration Agreement This amendment to the Collaboration Agreement (this “Amendment”) is made and entered into as of the 24th day of January, 2012 (the “Execution Date”), by and between Amgen Inc., a Delaware corporation with a place of business at 1 Amgen Center Drive, Thousand Oaks, CA 91320 (“Amgen”), and G

BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Collaboration Agreement

Amgen Inc

COLLABORATION AGREEMENT Collaboration Agreement Collaboration Agreement By and Between Amgen Inc. and Daiichi Sankyo Company, Limited Dated July 11, 2007 CONFIDENTIAL Amgen Contract #200710717 Note: Redacted portions have been marked with [*]. The redacted portions are subject to a request for confidential treatment that has been filed with the Securities and Exchange Commission. Table of Contents

PHARMACEUTICAL PREPARATIONS

INVESTOR AGREEMENT

Nektar Therapeutics

nktr-ex41_103.htm INVESTOR AGREEMENT This INVESTOR AGREEMENT (this “ Agreement ”) is made as of February 13, 2018, by and between Bristol-Myers Squibb Company, a Delaware corporation (the “ Investor ”), and Nektar Therapeutics, a Delaware corporation (the “ Company ”). WHEREAS, concurrently with the entering into of this Agreement, the Company and the Investor are entering into that certain Strat